The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells.

The subject matter described herein is directed to methods of producing decellularized and recellularized human prostate tissues and methods of treating disorders of a prostate, including BPH and prostate cancer, are disclosed. Prostate tissue engineering and the composition and construction of a prostate extracellular matrix (ECM) or a prostate tissue scaffold and interactions with its cellular components are also disclosed.

The present invention provides a primary cell culture which combines a cell culture medium and cells derived from a hypertrophied androgenic gland (AG) of a decapod crustacean. The invention also provides methods for obtaining an all-female progeny by initially injecting/transplanting the primary cell culture to a genetic-female to obtain a male-Neo-male.

The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells.

The present invention provides a primary cell culture which combines a cell culture medium and cells derived from a hypertrophied androgenic gland (AG) of a decapod crustacean. The invention also provides methods for obtaining an all-female progeny by initially injecting/transplanting the primary cell culture to a genetic-female to obtain a male-Neo-male.

The invention discloses a methodology for the culture of prostate tissue organoids from mouse and human prostate.

The present disclosure relates to use of a Dvl3-DEP peptide in the preparation of a medicament for repairing Sertoli cell injury in testes, and belongs to the technical field of medicine preparation. The Dvl3-DEP peptide is used in the preparation of a medicament for repairing Sertoli cell injury in testes, and the Dvl3-DEP peptide has an amino acid sequence shown in SEQ ID NO. 1. Tests prove that the overexpression of a Dvl3-DEP-coding gene significantly increases the level of cell resistance, repairs the tight junction function among Sertoli cells destructed by perfluorooctane sulphonate (PFOS) infection and enables a tight junction among Sertoli cells, and repairs the tight junction structure among Sertoli cells

A composition for treating a patient with a tissue disease or malformity has a composition containing amniotic fluid. The amniotic fluid has a quantity of gender specific amniotic fluid based on a gender of a fetal source. A method of treating a patient with a tissue disease or malformity comprises the steps of: identifying the tissue region to be treated and selecting a location to apply either topically or by injection or inhalation a composition containing amniotic fluid; selecting the composition containing amniotic fluid wherein the amniotic fluid has a quantity of gender specific amniotic fluid based on a gender of a fetal source allowing more specific targeted growth factors to be used for specific disease processes; and applying or injecting the composition at or into the selected location.

Disclosed is a method for in vitro reprogramming of fibroblasts into Sertoli cells and an application thereof. The method includes the following steps: introducing a fluorescent protein reporter system specifically expressed in the Sertoli cells into the fibroblasts; followed by introducing a substance that increases the expression level and/or activity of the NR5A1 protein; adding G418 and culturing for 3-7 d; discarding the liquid phase, adding a medium for culturing fibroblasts and continuing culturing for 3-7 d; and isolating the Sertoli cells from the culture system. Experiments showed that cells prepared by the method fully acquire the characteristics of Sertoli cells, such as attracting endothelial cells, forming lipid droplets, interacting with germ cells, inhibiting lymphocyte growth and interleukin production and having immune privilege. The disclosure has application value in the fields of infertility treatment, allogeneic transplantation, and cell therapy.

The present invention relates to organoids derived from a single cell, such as a prostate cancer cell, and methods and compositions relating to the production and use thereof, including cell culture medium for producing organoids and methods of personalized treatment for prostate cancer. The invention further provides a humanized mouse comprising a prostate organoid derived from a patient's prostate cell.